Bioluminescence Imaging to Detect Late Stage Infection of African Trypanosomiasis. by Burrell-Saward, Hollie & Ward, Theresa H
Burrell-Saward, H; Ward, TH (2016) Bioluminescence Imaging to De-
tect Late Stage Infection of African Trypanosomiasis. Journal of visu-




Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
	   	   	  
Page	  1	  of	  11	   	   	   	   	   	   	   	   	   	  	  	  rev.	   October	  
2013	  




Department	  of	  Infection	  and	  Immunity	  




Ward,	  Theresa	  H	  
Department	  of	  Infection	  and	  Immunity	  








Bioluminescence;	  firefly	  luciferase;	  CNS;	  optical	  imaging;	  trypanosomes;	  blood-­‐brain	  barrier;	  
mouse	  model;	  preclinical	  research.	  
	  
SHORT	  ABSTRACT:	  
This	  manuscript	   describes	   the	   use	   of	   a	   bioluminescent	   strain	   of	   African	   trypanosomes	   to	  
enable	  the	  tracking	  of	  late	  stage	  infection	  and	  demonstrates	  how	  in	  vivo	  live	  imaging	  can	  be	  
used	  to	  visualize	  infections	  within	  the	  central	  nervous	  system	  in	  real-­‐time.	  
	  
LONG	  ABSTRACT:	  	  
Human	  African	  trypanosomiasis	  (HAT)	  is	  a	  multi-­‐stage	  disease	  that	  manifests	  in	  two	  stages;	  
an	  early	  blood	  stage	  and	  a	  late	  stage	  when	  the	  parasite	  invades	  the	  central	  nervous	  system	  
(CNS).	  In	  vivo	  study	  of	  the	  late	  stage	  has	  been	  limited	  as	  traditional	  methodologies	  require	  
the	  removal	  of	  the	  brain	  to	  determine	  the	  presence	  of	  the	  parasites.	  
	  
Bioluminescence	   imaging	   is	   a	   non-­‐invasive,	   highly	   sensitive	   form	   of	   optical	   imaging	   that	  
enables	   the	   visualization	   of	   a	   luciferase-­‐transfected	   pathogen	   in	   real-­‐time.	   By	   using	   a	  
transfected	  trypanosome	  strain	  that	  has	  the	  ability	  to	  produce	  late	  stage	  disease	  in	  mice	  we	  
are	  able	  to	  study	  the	  kinetics	  of	  a	  CNS	  infection	  in	  a	  single	  animal	  throughout	  the	  course	  of	  
infection,	  as	  well	  as	  observe	  the	  movement	  and	  dissemination	  of	  a	  systemic	  infection.	  
	  
Here	  we	  describe	  a	  robust	  protocol	  to	  study	  CNS	  infections	  using	  a	  bioluminescence	  model	  
of	   African	   trypanosomiasis,	   providing	   real	   time	   non-­‐invasive	   observations	   which	   can	   be	  
further	  analyzed	  with	  optional	  downstream	  approaches.	  	  	  
	  
INTRODUCTION:	  
Human	  African	   trypanosomiasis	   (HAT),	  or	   sleeping	  sickness,	   is	   caused	  by	   the	  vector-­‐borne	  
protozoan	  parasites	  of	  the	  Trypanosoma	  brucei	  spp1.	  Estimated	  numbers	  of	  current	  cases	  is	  
fewer	  than	  7	  thousand	  every	  year	  with	  almost	  70	  million	  people	  exposed	  to	  the	  risk	  of	  the	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parasite	  infection	  within	  the	  African	  continent.	  The	  disease,	  which	  is	  most	  often	  lethal	  if	  left	  
untreated,	   comprises	   an	   early	   hemolymphatic	   stage	   where	   parasites	   are	   present	   in	   the	  
blood,	  progressing	  to	  the	  late	  stage	  when	  parasites	  invade	  the	  central	  nervous	  system	  (CNS)	  
and	  are	  no	  longer	  susceptible	  to	  treatment	  by	  early	  stage	  trypanosomal	  drugs2.	  The	  current	  
drug	  therapies	   for	   late-­‐stage	  HAT	  have	  both	  complex,	  prolonged,	   treatment	  regimens	  and	  
severe	   adverse	   effects	   as	   well	   as	   reported	   resistance,	   therefore	   research	   into	   new	   drug	  
therapies	  is	  imperative3,4.	  	  
	  
The	   study	   of	   late-­‐stage	   human	   African	   trypanosomiasis	   (HAT)	   within	   traditional	   mouse	  
models	  is	  lengthy	  and	  complex,	  with	  the	  removal	  of	  brain	  tissue	  being	  required	  to	  monitor	  
parasitic	   burden5.	   The	   animal	   infective	   strain	   T.	   b.	   brucei	   is	   used	   as	   the	   study	   model	   of	  
trypanosomiasis	  with	  the	  late	  stage	  appearing	  21	  days	  post	  infection	  (dpi).	  To	  monitor	  the	  
wild	  type	  nonbioluminescent	  parasite	  infection	  in	  the	  mouse	  model,	  peripheral	  blood	  films	  
or	  quantitative	  PCR	  are	  the	  only	  methods	  to	  determine	  parasite	  burden.	  For	  parasite	  burden	  
in	  the	  brain,	  the	  mouse	  needs	  to	  be	  culled,	  brain	  excised	  and	  qPCR	  carried	  out	  on	  tissues,	  
making	   it	   impossible	   to	   track	   parasites	   through	   multiple	   time	   points	   in	   the	   late	   stage	  
infection.	   This	   results	   in	   the	   inability	   to	   follow	   real-­‐time	   infections	   within	   the	   central	  
nervous	  system	  (CNS).	  	  
	  
In	  vivo	  bioluminescence	  imaging	  (BLI)	  can	  provide	  highly	  sensitive,	  non-­‐invasive	  detection	  of	  
parasite	  dissemination	  and	  disease	  progression	  in	  a	  mouse	  model	  that	  can	  be	  followed	  in	  a	  
single	  animal	  for	  the	  entirety	  of	  the	  experiment6.	  BLI	  is	  based	  on	  the	  emission	  of	  light	  in	  the	  
visible	  spectrum	  produced	  by	  a	  luciferase-­‐catalyzed	  reaction.	  The	  emitted	  photons	  are	  then	  
detected	   by	   a	   charge	   coupled	   device	   (CCD)	   camera7.	   For	   this	   purpose,	   the	   pathogen	   is	  
genetically	   modified	   to	   express	   a	   luciferase	   protein	   and	   the	   substrate,	   luciferin,	   is	  
introduced	  at	  time	  points	  of	  interest	  by	  injection.	  The	  main	  advantage	  of	  this	  method	  is	  the	  
ability	   to	   carry	   out	   longitudinal	   studies,	   in	  which	   the	   same	   animal	   can	   be	   imaged	   several	  
times	  with	  minimal	  adverse	  effects.	  The	  acquired	  bioluminescence	  signal	  can	  be	  quantified,	  
thus	  indicating	  the	  pathogen	  burden.	  
	  
The	  optimization	  and	  validation	  of	  a	  red-­‐shifted	  bioluminescent	  T.	  b.	  brucei	  has	  enabled	  the	  
investigation	   of	   the	   late	   stage	   infection	   through	   non-­‐invasive	   procedures,	   detecting	  
parasites	   earlier	   than	   blood	   film	   microscopy	   and	   greatly	   reducing	   the	   time,	   cost	   and	  
numbers	   of	   animals	   needed	   to	   study	   CNS	   infection	   and	   drug	   screening	   in	   late-­‐stage	  
trypanosomiasis8,9.	   In	   this	  protocol	  we	  demonstrate	   infection	  of	  mice	  with	  bioluminescent	  
trypanosomes	  and	  how	  to	  then	  visualize	  the	  parasites	   in	  vivo	   for	  quantification	  of	  disease	  





All	   work	   was	   carried	   out	   under	   the	   approval	   of	   the	   UK	   Home	   Office	   Animals	   (Scientific	  
Procedures)	   Act	   1986	   and	   the	   London	   School	   of	   Hygiene	   &	   Tropical	   Medicine	   Animal	  
Welfare	  and	  Ethics	  Review	  Board.	  ARRIVE	  guideline	  are	  followed	  in	  this	  report.	  
	  
1. In	  vivo	  passage	  of	  bioluminescent	  Trypanosoma	  brucei	  brucei	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1.1) Remove	  a	  cryopreserved	  stock	  (termed	  stabilate)	  of	  T.	  b.	  brucei	  strain	  GVR35-­‐VSL-­‐2	  
(available	   from	  Professor	   John	  Kelly	  at	   the	  London	  School	  of	  Hygiene	  &	  Tropical	  Medicine	  
through	  MTA)9	   from	   liquid	  nitrogen	  and	  allow	   to	  equilibrate	   to	   room	   temperature.	  Dilute	  
stabilate	  to	  2	  x	  104	  trypanosomes/ml	  in	  sterile	  phosphate	  buffered	  glucose	  saline	  (PBS-­‐G)	  pH	  
8.0	  (1	  litre	  PBS	  +	  15	  g	  glucose)10.	  	  
	  
1.2) Inject	   a	   20-­‐25	  g	   female	   CD1	   mouse	   with	   0.2	   ml	   diluted	   trypanosomes	   via	   the	  
intraperitoneal	  route	  (i.p.)	  with	  a	  25G	  needle.	  This	  is	  the	  “donor	  mouse”.	  Place	  the	  infected	  
mouse	  into	  a	  Specific	  Pathogen	  Free	  (SPF)-­‐cage	  and	  feed	  ad	  libitum.	  
	  
Note:	   CD1	   mice	   are	   an	   outbred	   strain	   and	   T.	   b.	   brucei	   GVR35	   infections	   are	   well-­‐
characterized	  in	  this	  strain.	  However,	  this	  protocol	  is	  also	  applicable	  to	  inbred	  or	  genetically-­‐
modified	  strains,	  but	  it	   is	   important	  to	  note	  that	  fur	  color	  may	  impact	  on	  the	  sensitivity	  of	  
imaging6,9.	  
	  
1.3) Monitor	   peripheral	   parasitemia	   by	   blood	   sampling.	   Place	   the	  mouse	   into	   a	   plastic	  
restrainer	   and	   take	   5	   μl	   of	   blood	   from	   the	   tail	   by	   venepuncture	   with	   21G	   needle	   or	  
venesection	  and	  mix	  1/10	  with	  0.85%	  sterile	  ammonium	  chloride	  to	  lyse	  red	  blood	  cells	  and	  
allow	  easier	  counting.	  	  
	  
1.4) Count	  the	  diluted	  blood	  in	  a	  Neubauer	  hemocytometer.	  	  
	  
1.4.1) Load	   the	   diluted	   blood	   into	   both	   chambers.	   Count	   the	   entire	   central	   grid	   of	   one	  
chamber	   to	   give	   n	   trypanosomes.	   Concentration	   of	   trypanosomes	   in	   blood	   =	   n	   x	   104	  
trypanosomes/ml,	   adjust	   for	   any	   dilution	   factor	   and	   calculate	   the	   average	   of	   the	   two	  
chambers.	  
	  
Note:	   After	   approximately	   5-­‐7	   days	   post-­‐infection,	   peripheral	   parasitemia	   should	   rise	  
sufficiently	  to	  carry	  out	  an	  infection	  at	  a	  concentration	  of	  2	  x	  104	  trypanosomes/ml.	  
	  
1.5) When	  trypanosome	  levels	  are	  high	  enough	  for	  the	  number	  of	  mice	  required,	  move	  
on	   to	   step	   1.6.	   A	   parasitemia	   level	   of	   6	   x	   104	   trypanosomes/ml	   in	   one	   donor	   mouse	   is	  
sufficient	  for	  infection	  of	  10	  mice.	  
	  
Note:	   For	   statistically	   significant	   group	   sizes,	  n	   =	   6	   for	   each	   treatment	   group	   of	  mice	   are	  
needed8.	   For	   other	  models	   of	   infection,	   power	   calculations	  would	   need	   to	   be	   applied	   to	  
determine	  appropriate	  group	  sizes.	  
	  
1.6) Place	  mice	  into	  a	  heat	  box	  (at	  28-­‐30	  °C	  for	  approximately	  5-­‐10	  minutes)	  to	  allow	  the	  
tail	   veins	   to	  dilate.	   To	   induce	   terminal	   anaesthesia,	   administer	   20	  mg/kg	  pentobarbital	   i.v	  
with	  a	  25G	  needle.	  Confirm	  mouse	  is	  anesthetized	  by	  gently	  pressing	  the	  footpads	  to	  ensure	  
there	  is	  no	  withdrawal	  reflex.	  	  
	  
1.7) Heparinize	  a	  21G	  needle	  by	  aliquoting	  5	  ml	  heparin	  at	  5000	  USP	  units/ml	  into	  a	  Bijou	  
tube	  and	  sucking	  twice	  in	  and	  out	  of	  the	  needle	  attached	  to	  a	  1	  ml	  syringe.	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1.8) Take	  the	  heparinized	  21G	  needle	  and	  1	  ml	  syringe,	  and	  perform	  cardiac	  puncture	  on	  
the	  anesthetized	  passage	  mouse	  by	  inserting	  the	  needle	  centrally	  underneath	  the	  rib	  cage	  
(a	  bead	  of	  blood	  will	  pool	  in	  the	  base	  of	  the	  needle)	  and	  gently	  pull	  back	  on	  the	  plunger	  so	  
as	  not	  to	  collapse	  the	  chamber	  of	  the	  heart.	  Collect	  a	  minimum	  of	  0.7	  ml	  of	  blood.	  	  
	  
1.9) Dilute	  infected	  blood	  to	  produce	  an	  inoculum	  of	  2	  x	  104	  trypanosomes/ml	  in	  PBS-­‐G	  
pH	  8.0	  as	  step	  1.1	  above.	  	  
	  
Note:	   At	   this	   point,	   the	   remaining	   blood	   can	   be	   cryopreserved	   to	   produce	   stabilate	   by	  
mixing	  with	  8%	  glycerol,	  20%	  heat-­‐inactivated	   foetal	  calf	   serum	  (hi-­‐FCS)	  and	  72%	   infected	  
blood.	  Slowly	  freeze	  at	  -­‐80°C	  using	  a	  slow-­‐freeze	  freezing	  container	  to	  achieve	  a	  cooling	  rate	  
of	  -­‐1°C/minute,	  before	  transferring	  to	  liquid	  nitrogen.	  
	  
2. Infection	  of	  experimental	  mice	  
	  
2.1) Place	  CD1	  female	  mice	  (approx.	  21-­‐25	  g)	  into	  a	  heating	  box	  to	  gently	  warm	  to	  dilate	  
veins.	   Place	   the	   warmed	  mice	   into	   a	   plastic	   restraint	   and	   inject	   0.2	   ml	   diluted	   inoculum	  
intravenously	  with	   a	   25G	   needle	   into	   the	   tail	   vein,	   equivalent	   to	   4000	   trypanosomes	   per	  
mouse.	  Place	  pressure	  at	  the	  injection	  site	  afterwards	  to	  stem	  the	  bleeding.	  	  
	  
Note:	   Intraperitoneal	   infection	   is	  a	  valid	   route	  of	   infection	  and	  has	  been	  used	   in	  previous	  
studies10,	  but	  we	  have	  found	  this	  less	  reproducible	  than	  the	  intravenous	  route.	  
	  
2.2) Randomize	  infected	  mice	  and	  cage	  in	  groups	  of	  3	  in	  SPF-­‐vented	  cages.	  As	  a	  control,	  
inject	  CD1	  female	  mice	  with	  wild	  type	  non-­‐bioluminescent	  parasite,	  T.	  b.	  brucei	  GVR35	  (n	  =	  
3).	  	  
	  
2.3) Monitor	  the	  infection	  through	  blood	  film	  microscopy	  	  
	  
2.3.1)	  Spot	  5	  μl	  blood	  from	  venepuncture	  or	  venesection	  onto	  a	  glass	  slide	  and	  perform	  a	  
blood	   smear	   (using	  a	   second	  glass	   slide	  gently	  push	   the	  drop	  of	  blood	  across	   the	   slide	   to	  
produce	  a	  thin	  film).	  Allow	  slides	  to	  air	  dry.	  	  
	  
2.3.2)	  Fix	  the	  blood	  smear	  with	  100%	  methanol	  and	  stain	  with	  Giemsa	  for	  10	  minutes	  before	  
rinsing	   with	   dH2O	   and	   allow	   to	   air	   dry.	   Under	   x100	   objective	   count	   the	   number	   of	  
trypanosomes	  in	  10	  fields	  of	  view	  (f.o.v.).	  
	  
Note:	  Blood	   filming	   is	   carried	  out	  alongside	  whole	  animal	  noninvasive	   imaging	  as	  early	  as	  
one	  day	  post-­‐infection.	  When	  processing	  a	  number	  of	  animals,	  this	  method	  of	  trypanosome	  
quantitation	   is	   preferred	   over	   hemocytometer	   counting	   as	   the	   samples	   can	   be	   stored	   at	  
room	  temperature	  and	  counted	  later.	  
	  
3. 	  Bioluminescence	  imaging	  to	  track	  infection	  
	  
Note:	  To	  monitor	  the	  infection,	  whole	  animal	  non-­‐invasive	  imaging	  can	  be	  used.	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3.1) Prepare	  a	  stock	  solution	  of	  D-­‐luciferin,	  the	  firefly	  luciferase	  substrate,	  in	  Dulbecco’s	  
Phosphate	  Buffered	  Saline	  (DPBS)	  at	  30	  mg/ml.	  Filter	  sterilize	  and	  freeze	  in	  aliquots	  at	  -­‐20°C.	  	  
	  
Note:	   D-­‐Luciferin	   is	   light	   sensitive,	   therefore	  protect	   it	   from	   light	   by	  wrapping	   aliquots	   in	  
foil.	  Do	  not	  repeatedly	  freeze-­‐thaw	  luciferin	  as	  it	  can	  affect	  activity11.	  	  
	  
3.2) Warm	  an	  aliquot	  of	  D-­‐luciferin	  to	  room	  temperature.	  Remove	  each	  mouse	  from	  the	  
cage	  (including	  control	  mice	  infected	  with	  nonbioluminescent	  wild	  type	  parasite	  strain)	  and	  
inject	  150	  mg/kg	  of	   the	  warmed	  D-­‐luciferin	   (diluted	   in	  DPBS)	   intraperitoneally	  with	  a	  25G	  
needle.	  Place	  the	  mice	  into	  an	  isofluorane	  chamber	  for	  approximately	  5	  minutes	  to	  induce	  
anesthesia	  with	  2%	  isofluorane/O2	  mix	  at	  2.5	  L/min.	  	  
	  
Note:	  Mice	  become	  immobile	  when	  they	  are	  under	  anesthesia.	  For	  the	  imager	  used	  here,	  3	  
mice	   can	   be	   processed	   at	   a	   time.	   If	   mice	   are	   anesthetized	   for	   longer	   than	   30	   minutes,	  
ophthalmic	   artificial	   tear	   ointment	   can	   be	   applied	   to	   prevent	   the	   eyes	   of	   the	  mice	   from	  
drying	  out.	  	  
	  
3.3) For	   the	   imager	  described	  here,	  open	   the	   software	  and	   initialize	   the	  machine	  using	  
the	   software	  as	  per	  manufacturer’s	   instructions.	  Acquire	   images	  once	  camera	  and	  heated	  
plate	  have	  reached	  temperature.	  
	  
Note:	   This	   instrument	   is	   not	   usually	   switched	   off,	   enabling	   the	   machine	   to	   perform	  
background	   calibrations	   overnight.	   In	   the	   event	   that	   it	   needs	   to	   restart,	   it	   must	   run	   a	  
calibration	  check	  first.	  
	  
3.4) Place	   the	   anesthetized	  mice	   into	   the	   imager	   (see	   3.5).	   Use	   large	   black	   separators	  
between	   the	  mice	   to	  minimize	   bleed	   through	   of	   any	   bright	   bioluminescent	   signal.	   Image	  
mice	  using	  a	  set	  of	  exposure	  times;	  1,	  3,	  10,	  30,	  60	  and	  180	  seconds,	  with	  medium	  binning,	  1	  
f/stop	  and	  an	  open	  filter,	  and	  field	  of	  view	  E	  (12.5	  x	  12.5	  cm).	  	  
	  
Note:	   The	   control	   mice	   infected	   with	   the	   wild	   type	   nonbioluminescent	   GVR35	   parasites	  
provide	  a	  background	  bioluminescence	  value.	  From	  a	  luciferin	  kinetics	  experiment	  (Figure	  6)	  
with	   this	   model,	   we	   have	   found	   that	   bioluminescence	   signal	   peaks	   at	   10	   minutes	   post	  
administration	  and	   imaging	  takes	  approximately	  5	  minutes	   for	  3	  mice.	  Take	  this	   timescale	  
into	  consideration	  when	  anesthetizing	  and	  imaging	  the	  mice.	  
	  
3.5) To	  ensure	  thorough	  imaging	  of	  the	  mice,	  rotate	  to	  obtain	  a	  ventral,	  dorsal	  and	  lateral	  
view.	   Maintain	   consistency	   in	   the	   order	   of	   orientation	   for	   imaging	   between	   sequential	  
animals.	  
	  
3.6) After	   imaging,	   allow	   mice	   to	   recover	   from	   anesthesia	   under	   observation	   before	  
returning	  to	  SPF-­‐cage.	  
	  
3.7) Continue	   imaging	  mice	  every	  7	  days	  until	  day	  21	  post-­‐infection.	  There	  should	  be	  a	  
steady	  increase	  in	  bioluminescence	  signal	  over	  the	  entire	  animal.	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3.8) At	   D21,	   image	   and	   blood	   film	   the	   mice	   as	   described	   above,	   and	   dose	   mice	   with	  
40	  mg/kg	   diminazene	   aceturate	   intraperitoneally.	   This	   drug	   will	   clear	   the	   peripheral	  
parasitemia	   but	   will	   not	   cross	   the	   blood-­‐brain	   barrier,	   and	   therefore	   enables	   better	  
visualization	  of	  the	  CNS	  infection.	  	  
	  
Note:	   Diminazene	   aceturate	   is	   a	   well-­‐established	   drug	   used	   to	   treat	   early-­‐stage	   animal	  
trypanosomiasis.	  
	  
3.9) Continue	  imaging	  and	  monitoring	  at	  D28	  and	  D35.	  
	  
4.	  	   Confirming	  CNS	  infection	  
	  
4.1)	   At	  D35,	  image	  mice	  as	  detailed	  above	  (steps	  3.1-­‐3.4).	  	  
	  
4.2)	  	   After	   imaging,	   allow	   mice	   to	   recover	   from	   anesthesia	   and	   exsanguinate	   mice	   as	  
detailed	  in	  step	  1.6-­‐1.8,	  collecting	  blood	  for	  further	  analysis.	  
	  
4.3)	   Following	  cardiac	  puncture,	  perfuse	  mice	  with	  20	  ml	  PBS	  (optional:	  add	  3	  mg/ml	  of	  
luciferin	   to	   perfusion	   solution)	   via	   the	   heart	   to	   clear	   blood	   from	   the	   organs	   and	   to	  
reintroduce	   luciferin	   label	   that	   might	   have	   cleared	   from	   the	   brain	   region	   over	   the	   time	  
interval	  from	  step	  4.1.	  
	  
4.4)	   Gently	  remove	  the	  brain,	  by	  using	  curved	  scissors,	  cutting	  from	  the	  base	  around	  the	  
circumference	  of	  the	  skull,	  and	  lifting	  off	  the	  top	  part	  of	  the	  skull,	  to	  allow	  the	  brain	  to	  be	  
gently	  lifted	  out	  with	  curved	  forceps.	  	  
	  
4.5)	   Place	  the	  excised	  brain	  onto	  a	  section	  of	  black	  plastic	  and	  pipette	  50	  µl	  of	  15	  mg/ml	  
luciferin	  over	  the	  organ	  prior	  to	  imaging,	  to	  ensure	  adequate	  luciferin	  has	  been	  added	  to	  the	  
excised	  brain.	   Image	  using	   the	  settings	  as	  above.	  This	  will	  demonstrate	   localization	  of	   the	  
infection	  to	  the	  brain	  hemispheres.	  
	  
Note:	  Downstream	  quantification	  of	  parasitemia	  on	  the	  excised	  brain	  can	  be	  carried	  out	  by	  
qPCR	   as	   previously	   described8.	   Other	   alternative	   downstream	   applications	   might	   include	  
histology	   or	   immunohistochemistry	   to	   identify	   parasites	   in	   the	   brain	   tissue	   following	  
fixation.	  
	  
5. Quantitation	  of	  bioluminescence	  imaging	  
	  
Note:	  Bioluminescence	  can	  be	  quantified	  using	  the	  region	  of	  interest	  (ROI)	  with	  the	  imaging	  
software	  and	  corrected	  for	  background	  bioluminescence.	  
	  
5.1)	   Using	   the	   ROI	   tool,	   create	   a	   rectangular	   ROI	   for	   whole	   animal	   quantitation	   and	  
position	  it	  over	  the	  mouse	  image	  to	  cover	  tip	  of	  the	  nose	  to	  base	  of	  the	  tail	  of	  the	  mouse.	  
Use	  the	  same	  size	  box	  for	  every	  animal	  and	  every	  time	  point.	  When	  looking	  at	  the	  ROI	  for	  
the	  brain,	  use	  a	  circular	  ROI	  in	  the	  same	  way,	  positioning	  it	  over	  the	  mouse	  head	  region	  in	  
the	  image.	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5.2)	   If	  desired,	  adjust	  images	  to	  appear	  on	  the	  same	  spectrum	  for	  a	  visual	  representation	  
of	  infection.	  	  
	  
Note:	  The	  software	  used	  here	  generates	  a	  color	  map	  for	  each	  image	  automatically	  adjusted	  
for	  minimum	  and	  maximum	  photon	  counts.	  To	  enable	  visual	  comparison	  between	  a	  series	  
of	  images,	  the	  color	  scale	  must	  be	  set	  to	  the	  same	  values	  for	  all	  images.	  
	  
5.2.1)	  	   Using	  the	  image	  with	  the	  highest	  bioluminescence	  and	  the	  ‘Image	  adjust’	  tab	  on	  the	  
tool	   palette,	   select	   a	   logarithmic	   scale	   and	   an	   appropriate	   color	   scale	   minimum	   and	  
maximum	   (to	   be	   determined	   empirically).	   Apply	   this	   scale	   to	   all	   images	   throughout	   the	  
experiment.	  
	  
REPRESENTATIVE	  RESULTS:	  	  
This	  protocol	  demonstrates	  how	   to	   follow	  disease	  progression	   following	   infection	  of	  mice	  
with	  T.	  b.	  brucei,	  a	  model	  for	  human	  African	  trypanosomiasis.	  Figure	  1	  shows	  the	  timeline	  of	  
the	  experimental	  protocol,	  demonstrating	   the	   timetable	   for	   treatment	  and	   imaging	   steps.	  
Figure	  2	  demonstrates	  a	  typical	  field	  of	  view	  in	  a	  fixed	  Giemsa-­‐stained	  blood	  smear	  used	  to	  
quantitate	   peripheral	   parasitemia,	   with	   trypanosomes	   and	   red	   blood	   cells	   present.	  
Development	  of	  the	  infection	  in	  animals	  can	  be	  followed	  by	  measuring	  the	  bioluminescence	  
as	  in	  Figure	  3,	  which	  shows	  the	  infected	  animals	  over	  the	  course	  of	  an	  experiment	  with	  the	  
same	   animals	   imaged	   at	   each	   time	   point.	   Through	   the	   course	   of	   infection	   an	   increase	   in	  
bioluminescence	   can	   be	   observed	   in	   all	   the	   animals	   over	   the	   first	   21	   days	   as	   the	   signal	  
becomes	  more	  disseminated	  and	  intense,	  with	  high	  regions	  of	  BLI	  (represented	  as	  red	  from	  
the	  heat	  map	  scale)	  in	  the	  spleen	  area.	  At	  D21	  mice	  are	  treated	  with	  diminazene	  aceturate	  
as	  detailed	  in	  Figure	  1,	  post-­‐imaging,	  and	  a	  drop	  in	  bioluminescence	  can	  be	  observed	  at	  D28	  
as	   the	   peripheral	   infection	   is	   cleared,	  with	   low	   levels	   of	   signal	   being	   present	   in	   the	   head	  
region	  of	  the	  mice.	  At	  D35	  the	  signal	  still	  remains	  in	  the	  head	  region	  and	  has	  become	  more	  
intense	  indicating	  a	  possible	  brain	  infection.	  The	  brain	  is	  excised	  to	  confirm	  signal	  is	  present	  
within	  the	  brain	  tissue	  and	  can	  then	  be	  quantitated	  by	  qPCR.	  
	  
Traditionally,	   blood	   smears	   are	   used	   to	   quantitate	   infection	   progression	   and	   treatment	  
effects.	   However,	   these	   only	   measure	   peripheral	   parasitemia,	   and	   cannot	   be	   used	   to	  
evaluate	  parasite	  levels	  in	  the	  brain.	  Figure	  4	  combines	  quantitation	  of	  both	  the	  peripheral	  
parasitemia	  and	  bioluminescence	  to	  demonstrate	  disease	  kinetics.	  At	  D7	  a	  high	  BLI	  signal	  is	  
present	  of	  108	  photons/second,	  but	  the	  parasitemia	  is	  very	  low	  within	  the	  blood	  films.	  Both	  
the	   parasitemia	   and	   signal	   then	   increase	   and	   at	   D21	   the	   parasitemia	   drops	   but	  
bioluminescence	   remains	   constant	  which	   is	   in	   part	   due	   to	   the	   trypanosomes	  moving	   into	  
the	  lymphatic	  system	  and	  tissues	  and	  also	  due	  their	  host-­‐evasion	  method	  of	  switching	  their	  
surface	  glycoproteins	  (VSG).	  After	  D21	  the	  parasitemia	  becomes	  undetectable	  in	  the	  blood	  
films	   due	   to	   the	   treatment	   with	   diminazene	   aceturate	   but,	   despite	   the	   initial	   dip	   in	  
bioluminescence,	   the	   signal	   is	   still	   above	  background	  and	  continues	   to	  D35,	   a	  measure	  of	  
the	   bioluminescence	   in	   the	   head	   region	   seen	   in	   Figure	   3.	   This	   demonstrates	   the	   greater	  
sensitivity	  of	  the	  bioluminescence	  approach	  over	  traditional	  blood	  film	  counting.	  	  
	  
To	  verify	  that	  the	  bioluminescence	  in	  the	  head	  region	  is	  truly	  localizing	  to	  brain	  tissue,	  at	  the	  
end	  of	  the	  experiment	  the	  brains	  are	  excised	  and	  bioluminescence	  measured	  ex	  vivo	  (Figure	  
5).	  A	  difference	  in	  infection	  burden	  between	  brains	  is	  often	  seen	  and	  signal	  does	  not	  appear	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to	   localize	   to	   specific	   anatomical	   regions	   as	   distribution	   of	   intense	   BLI	   signal	   can	   vary	  
between	  infected	  animals.	  For	  example,	  strong	  BLI	  signal	  is	  present	  in	  the	  olfactory	  bulb	  in	  
mouse	   2	   and	   3	   and	   in	   the	   cerebellum	   in	  mouse	   3,	   while	   the	   brain	   from	  mouse	   1	   shows	  
general	  distribution	  of	  BLI	  signal	  all	  over	  the	  brain.	  As	  the	  brains	  can	  be	  imaged	  immediately	  
after	  culling	  the	  mice,	  further	  analysis	  can	  be	  carried	  out	  on	  the	  brain	  tissue	  as	  the	  tissue	  is	  
not	  damaged	  in	  the	  ex	  vivo	  imaging	  process.	  
	  
Figure	  Legends:	  	  
	  
Figure	  1:	  Timeline	  of	  experiment	   including	   imaging,	   sampling	  and	   treatment.	  Due	  to	  the	  
non-­‐invasive	   nature	   of	   bioluminescence	   imaging,	  monitoring	   of	   infection	   can	   occur	  more	  
often	   than	   detailed	   in	   the	   diagram.	   The	   sampling	   and	   imaging	   every	   7	   days	   enable	   the	  
identification	  of	  the	  progressing	  infection.	  The	  treatment	  at	  D21	  with	  diminazene	  aceturate	  
removes	  peripheral	  parasitemia	  to	  allow	  better	  visualization	  of	  the	  head	  and	  brain	  infection.	  
Diminazene	  aceturate	  is	  an	  early	  stage	  drug	  and	  is	  not	  able	  to	  pass	  the	  blood-­‐brain	  barrier	  in	  
quantities	  adequate	  to	  clear	  the	  late	  stage	  infection.	  	  
	  
Figure	   2:	   Giemsa	   stained	   trypanosomes.	   On	   a	   fixed	   blood	   film,	   Giemsa	   stained	  
trypanosomes	  (purple	  with	  pink	  nuclei,	  closed	  arrow)	  are	  easily	  detectable	  against	  the	  red	  
blood	  cells	  (stained	  blue,	  open	  arrow)	  and	  can	  be	  quickly	  counted	  to	  obtain	  the	  number	  of	  
trypanosomes/	  10	  fields	  of	  view	  under	  a	  100x	  objective.	  The	  scale	  bar	  denotes	  10	  μm.	  
	  
Figure	   3:	   Bioluminescence	   imaging	   of	   infected	   mice.	   Three	   representative	   animals	   of	   a	  
group	  of	  6	  mice	  infected	  with	  VSL-­‐2	  (M	  =	  mouse)	  and	  a	  wild	  type	  infected	  control	  (infected	  
with	  the	  wild	  type	  nonbioluminescent	  parasite	  line).	  Luciferin	  was	  also	  administered	  to	  the	  
control	  mouse	  prior	  to	  imaging,	  which	  provides	  the	  background	  measurement.	  A	  heat	  map	  
scale	  is	  shown	  with	  red	  indicating	  high	  levels	  of	  bioluminescence,	  equating	  to	  high	  numbers	  
of	  parasites,	  and	  blue	  indicating	  low	  levels	  of	  bioluminescence	  (D	  =	  day).	  The	  control	  mouse	  
has	   no	   bioluminescence	   as	   expected	   with	   no	   luciferase-­‐expressing	   parasites.	   Image	   from	  
Burrell-­‐Saward	  et	  al8	  by	  permission	  of	  Oxford	  University	  Press.	  
	  
Figure	   4:	   Comparison	   of	   bioluminescence	   and	   blood	   film	   parasitemia.	   Total	  
bioluminescence	   of	   each	   whole	   animal	   was	   quantitated	   as	   described	   in	   section	   5	   and	  
peripheral	  parasitemia	  quantitated	  by	  counting	  parasites	  in	  blood	  smears.	  Error	  bars	  denote	  
standard	   deviation	   from	   the	   mean.	   Image	   from	   Burrell-­‐Saward	   et	   al8	   by	   permission	   of	  
Oxford	  University	  Press.	  
	  
Figure	  5:	  Ex	  vivo	  imaging	  of	  excised	  brain.	  The	  perfused	  brains	  of	  the	  mice	  imaged	  in	  Figure	  
3	  were	   removed	  and	   imaged	  as	  described	   in	  4.5.	  Bioluminescence	   is	  measured	  on	  a	  heat	  
map	   scale	   as	   for	   Figure	   3.	   The	   control	   brain	   from	   a	   mouse	   infected	   with	   wild	   type	  
nonbioluminescent	  parasites	  was	  also	  treated	  with	  luciferin	  and	  no	  bioluminescence	  can	  be	  
observed.	  The	  scale	  bar	  denotes	  1	  cm.	  This	  figure	  has	  been	  modified	  from	  Burrell-­‐Saward	  et	  
al8	  by	  permission	  of	  Oxford	  University	  Press.	  
	  
Figure	  6:	  Kinetics	  of	  luciferin	  bioluminescence	  in	  VSL-­‐2-­‐infected	  mice.	  Three	  VSL-­‐2-­‐infected	  
CD1	  mice	  were	   injected	  with	  150	  mg/kg	   i.p	  of	   luciferin	  and	  placed	  immediately	  within	  the	  
imager.	  The	  mice	  were	  imaged	  over	  60	  minutes	  and	  their	  bioluminescence	  was	  calculated	  to	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determine	  the	  optimum	  imaging	  window	  after	  luciferin	  administration.	  	  
	  
DISCUSSION:	  
The	  development	  of	  a	  bioluminescent	  T.	  b.	  brucei	  GVR35	  strain	  allows	  the	  visualization	  of	  a	  
trypanosome	   infection	   from	   the	   early	   to	   the	   late	   stage.	   Previous	   infection	   models	   were	  
unable	  to	  detect	  the	  late	  stage,	  when	  parasites	  are	  in	  the	  brain,	  in	  real	  time	  from	  blood	  film	  
microscopy,	   and	   required	   the	   culling	   and	   removal	   of	   brains	   from	   the	   infected	   mice	   to	  
determine	   parasite	   burden12.	   The	   bioluminescence	   reduces	   inter-­‐mouse	   variability	   as	   a	  
single	  mouse	  can	  be	  tracked	  throughout	  the	  entirety	  of	  the	  infection	  and	  a	  quick	  qualitative	  
assessment	   of	   infection	   can	   be	   observed	   at	   any	   stage.	   The	   highly	   sensitive	   method	   of	  
bioluminescence	  imaging	  enables	  low-­‐level	  infection	  to	  be	  identified	  earlier	  than	  blood-­‐film	  
microscopy,	  with	  as	  few	  as	  100	  trypanosomes	  detectable	  through	  imaging	  compared	  to	  the	  
5	  x	  103	   trypanosomes/ml	  detectable	  through	  microscopy9.	   In	  addition,	   following	  the	  same	  
animals	  throughout	  the	  experiment	  eliminates	  the	  need	  for	  separate	  animal	  groups	  for	  each	  
time	  point,	  greatly	  reducing	  animal	  usage.	  
	  
The	  imaging	  protocol	  described	  here	  can	  be	  adapted	  to	  suit	  the	  scientific	  need	  as	  the	  non-­‐
invasive	  nature	  means	  that	  additional	  and	  more	  frequent	  imaging	  can	  be	  carried	  out	  (with	  
appropriate	   animal	   ethics	   approval),	   but	   for	   the	   assessment	   of	   brain	   infection	  D21	   is	   the	  
earliest	  time	  point.	  At	  this	  point,	  early	  stage	  drugs	  are	  no	  longer	  effective	  at	  clearing	  the	  late	  
stage	  parasites.	  It	  is	  also	  imperative	  that	  the	  mice	  are	  imaged	  under	  the	  same	  conditions	  at	  
each	  time	  point.	  For	  example,	  the	  same	  exposure	  times	  and	  same	  view	  (ventral	  or	  dorsal)	  
should	  be	  used	  to	  ensure	  accurate	  measurement	  of	  the	  course	  of	  infection.	  
	  
If	   during	   imaging	   no	   signal	   is	   present	   (when	   it	   is	   known	   that	   the	  model	   should	   have	   an	  
infection),	  there	  are	  a	  number	  of	  steps	  that	  can	  be	  followed	  to	  determine	  the	  source	  of	  the	  
problem.	   Firstly,	   the	   exposure	   time	   can	   be	   increased	   to	   a	  maximum	   of	   5	  minutes	   which	  
should	  be	  able	  to	  detect	  very	  low	  bioluminescence	  signal.	  If	  signal	  is	  still	  not	  detected	  and	  
blood	  films	  are	  positive	  for	  parasite,	  the	  next	  step	  would	  be	  to	  confirm	  whether	  the	  parasite	  
is	   still	   bioluminescent.	   This	   can	   be	   carried	   out	   by	   using	   a	   commercial	   in	   vitro	   luciferase	  
activity	  assay	  and	  bioluminescence	  would	  be	  detected	  using	  a	  luminometer.	  If	  at	  this	  point	  
the	  parasite	  is	  no	  longer	  bioluminescent,	  the	  stability	  of	  the	  construct	  in	  the	  parasite	  would	  
need	  to	  be	  addressed.	  
	  
The	   color	   of	   the	   mice	   makes	   a	   difference	   to	   the	   sensitivity	   of	   imaging	   as	   the	   emitted	  
bioluminescence	  is	  attenuated	  by	  dark	  fur	  and	  skin6,9.	  Choice	  of	  mouse	  strain,	  such	  as	  white	  
mice	   or	   nude	   mice,	   can	   therefore	   improve	   results.	   If	   mouse	   color	   is	   constrained,	   for	  
example	   by	   use	   of	   a	   transgenic	   line,	   then	   shaving	   or	   depilating	   the	   mice	   in	   a	   region	   of	  
interest	  can	  greatly	  improve	  sensitivity6.	  
	  
Despite	   the	   improved	   sensitivity	   and	   signal	   that	   bioluminescent	   model	   produces,	   the	  
bioluminescence	  does	  not	  directly	  correlate	  to	  the	  peripheral	  parasitemia	  observed	  in	  blood	  
films	  (days	  7-­‐21	  shown	  in	  Figure	  4).	  Literature	  has	  documented	  that	  the	  early	  stage	  infection	  
of	   trypanosomiasis	   infects	   the	  hemolymphatic	   system1,	   and	   is	   not	   solely	   restricted	   to	   the	  
blood	  system	  and	  this,	  along	  with	  the	  infection	  of	  peripheral	  organs,	  may	  explain	  why	  when	  
peripheral	  parasitemia	  is	  barely	  detectable	  in	  the	  blood	  films,	  bioluminescence	  is	  visible	  as	  
is	  particularly	  apparent	  from	  the	  data	  for	  day	  7	  in	  Figure	  3	  and	  4.	  This,	  however,	  does	  mean	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that	  bioluminescence	  imaging	  can	  only	  be	  used	  as	  a	  qualitative	  measurement	  of	   infection,	  
and	  further	  analysis	  is	  required	  to	  determine	  absolute	  parasite	  burden.	  
	  
Bioluminescence	   imaging	  has	  the	  capability	  of	  being	  used	  with	  other	   infectious	  pathogens	  
that	   are	   difficult	   to	   monitor,	   with	   rodent	   models	   of	   Chagas	   disease,	   malaria	   and	  
toxoplasmosis	   already	   established13-­‐16.	   The	   high	   signal-­‐to-­‐noise	   ratio	   of	   bioluminescence	  
coupled	   with	   its	   ability	   to	   track	   real-­‐time	   infections	   can	   provide	   a	   more	   sensitive,	   non-­‐
invasive	  drug	  assessment,	  as	  well	  as	  gain	  a	  better	  understanding	  of	  CNS	  infection	  kinetics,	  
making	  it	  a	  valuable	  tool	  in	  infectious	  disease	  research.	  
	  
ACKNOWLEDGMENTS:	  
We	  thank	  John	  Kelly	  and	  Martin	  Taylor	  (London	  School	  of	  Hygiene	  &	  Tropical	  Medicine)	  for	  
providing	   T.	   b.	   brucei	   GVR35-­‐VSL-­‐2	   and	   Dr.	   Andrea	   Zelmer	   (LSHTM)	   for	   advice	   on	   in	   vivo	  
imaging.	  This	  work	  was	  supported	  by	  the	  Bill	  and	  Melinda	  Gates	  Foundation	  Global	  Health	  
Program	  (grant	  number	  OPPGH5337).	  
	  
DISCLOSURES:	  	  
The	  authors	  have	  nothing	  to	  disclose.	  
	  
REFERENCES	  	  
1.	   Brun,	  R.,	  Blum,	  J.,	  Chappuis,	  F.,	  Burri,	  C.	  Human	  African	  trypanosomiasis.	  Lancet	  
375(9709),	  148-­‐159,	  doi:10.1016/S0140-­‐6736(09)60829-­‐1	  (2010).	  
2.	   Rodgers,	  J.	  Trypanosomiasis	  and	  the	  brain.	  Parasitology	  137(14),	  1995-­‐2006,	  
doi:10.1017/S0031182009991806	  (2010).	  
3.	   Barrett,	  M.P.,	  Boykin,	  D.W.,	  Brun,	  R.,	  Tidwell,	  R.R.	  Human	  African	  trypanosomiasis:	  
pharmacological	  re-­‐engagement	  with	  a	  neglected	  disease.	  Br.	  J.	  Pharmacol.	  152(8),	  
1155-­‐1171	  (2007).	  
4.	   Barrett,	  M.P.,	  Vincent,	  I.M.,	  Burchmore,	  R.J.S.,	  Kazibwe,	  A.J.N.,	  Matovu,	  E.	  Drug	  
resistance	  in	  human	  African	  trypanosomiasis.	  Future	  Microbiol.	  6(9),	  1037-­‐1047,	  
doi:10.2217/fmb.11.88	  (2011).	  
5.	   Jennings,	  F.W.,	  Whitelaw,	  D.D.,	  Urquhart,	  G.M.	  The	  relationship	  between	  duration	  of	  
infection	  with	  Trypanosoma	  brucei	  in	  mice	  and	  the	  efficacy	  of	  chemotherapy.	  
Parasitology	  75(2),	  143-­‐153	  (1977).	  
6.	   Andreu,	  N.,	  Zelmer,	  A.,	  Wiles,	  S.	  Noninvasive	  biophotonic	  imaging	  for	  studies	  of	  
infectious	  disease.	  FEMS	  Microbiol.	  Rev.	  35(2),	  360-­‐394,	  doi:10.1111/j.1574-­‐
6976.2010.00252.x	  (2011).	  
7.	   Sadikot,	  R.T.,	  Blackwell,	  T.S.	  Bioluminescence	  imaging.	  Proc.	  Am.	  Thorac.	  Soc.	  2(6),	  
537-­‐540,	  doi:10.1513/pats.200507-­‐067DS	  (2005).	  
8.	   Burrell-­‐Saward,	  H.,	  Rodgers,	  J.,	  Bradley,	  B.,	  Croft,	  S.L.,	  Ward,	  T.H.	  A	  sensitive	  and	  
reproducible	  in	  vivo	  imaging	  mouse	  model	  for	  evaluation	  of	  drugs	  against	  late-­‐stage	  
human	  African	  trypanosomiasis.	  J.	  Antimicrob.	  Chemother.	  70(2),	  510-­‐517,	  
doi:10.1093/jac/dku393	  (2015).	  
9.	   McLatchie,	  A.P.,	  et	  al.	  Highly	  sensitive	  in	  vivo	  imaging	  of	  Trypanosoma	  brucei	  
expressing	  "red-­‐shifted"	  luciferase.	  PLoS	  Negl.	  Trop.	  Dis.	  7(11),	  e2571,	  
doi:10.1371/journal.pntd.0002571	  (2013).	  
	   	   	  
Page	  11	  of	  11	   	   	   	   	   	   	   	   	   	  	  	  rev.	   October	  
2013	  
10.	   Jennings,	  F.W.,	  et	  al.	  Human	  African	  trypanosomiasis:	  potential	  therapeutic	  benefits	  
of	  an	  alternative	  suramin	  and	  melarsoprol	  regimen.	  Parasitol.	  Int.	  51(4),	  381-­‐388	  
(2002).	  
11.	   Wiles,	  S.,	  Robertson,	  B.D.,	  Frankel,	  G.,	  Kerton,	  A.	  Bioluminescent	  monitoring	  of	  in	  
vivo	  colonization	  and	  clearance	  dynamics	  by	  light-­‐emitting	  bacteria.	  Methods	  Mol.	  
Biol.	  574,	  137-­‐153,	  doi:10.1007/978-­‐1-­‐60327-­‐321-­‐3_12	  (2009).	  
12.	   Rodgers,	  J.,	  Bradley,	  B.,	  Kennedy,	  P.G.E.	  Combination	  chemotherapy	  with	  a	  
substance	  P	  receptor	  antagonist	  (aprepitant)	  and	  melarsoprol	  in	  a	  mouse	  model	  of	  
human	  African	  trypanosomiasis.	  Parasitol.	  Int.	  56(4),	  321-­‐324	  (2007).	  
13.	   Kamerkar,	  S.,	  Davis,	  P.H.	  Toxoplasma	  on	  the	  brain:	  understanding	  host-­‐pathogen	  
interactions	  in	  chronic	  CNS	  infection.	  J.	  Parasitol.	  Res.	  2012,	  589295,	  
doi:10.1155/2012/589295	  (2012).	  
14.	   Franke-­‐Fayard,	  B.,	  et	  al.	  Murine	  malaria	  parasite	  sequestration:	  CD36	  is	  the	  major	  
receptor,	  but	  cerebral	  pathology	  is	  unlinked	  to	  sequestration.	  Proc.	  Natl.	  Acad.	  Sci.	  
U.S.A.	  102(32),	  11468-­‐11473,	  doi:10.1073/pnas.0503386102	  (2005).	  
15.	   Hitziger,	  N.,	  Dellacasa,	  I.,	  Albiger,	  B.,	  Barragan,	  A.	  Dissemination	  of	  Toxoplasma	  
gondii	  to	  immunoprivileged	  organs	  and	  role	  of	  Toll/interleukin-­‐1	  receptor	  signalling	  
for	  host	  resistance	  assessed	  by	  in	  vivo	  bioluminescence	  imaging.	  Cell.	  Microbiol.	  7(6),	  
837-­‐848,	  doi:10.1111/j.1462-­‐5822.2005.00517.x	  (2005).	  
16.	   Lewis,	  M.D.,	  et	  al.	  Bioluminescence	  imaging	  of	  chronic	  Trypanosoma	  cruzi	  infections	  
reveals	  tissue-­‐specific	  parasite	  dynamics	  and	  heart	  disease	  in	  the	  absence	  of	  locally	  
























































B io lu m in e s c e n c e
T im e  p o s t- in fe c t io n
















































P a ra s ita e m ia






Name	  of	  Material	  /Equipment Company Catalogue	  Number Comments/Description
PBS Sigma,	  UK P4417 tablets	  pH	  7.4
Glucose Sigma,	  UK G8270 99.5%	  (molecular)	  grade
Ammonium	  chloride Sigma,	  UK A9434 99.5%	  (molecular)	  grade
Heparin	  (lithium	  salt) Sigma,	  UK H0878
Hi-­‐FCS Gibco,	  Life	  Technologies,	  UK 10500-­‐064 500	  ml
DPBS Sigma,	  UK D4031 Sterile	  filtered
Mr.	  Frosty Nalgene,	  UK
Giemsa Sigma,	  UK G5637
Perkin	  Elmer,	  UK
Sigma,	  UK 115144-­‐35-­‐9
Diminazene	  aceturate Sigma,	  UK D7770 Analytical	  grade
IVIS	  Lumina	  II Perkin	  Elmer,	  UK
other	  bioimagers	  available	  e.g.	  from	  
Bruker,	  Kodak
Living	  Image	  v.	  4.2 Perkin	  Elmer,	  UK
proprietary	  software	  for	  Perkin	  Elmer	  IVIS	  
instruments;	  other	  instruments	  may	  have	  
their	  own
1	  ml	  syringe Fisher	  Scientific,	  UK 10142104
20	  ml	  syringe Fisher	  Scientific,	  UK 10743785
25G	  Needles Greiner	  Bio-­‐one N2516
21G	  Needles Greiner	  Bio-­‐one N2138
Twin-­‐frosted	  microscope	  slide VWR,	  UK 631-­‐0117
1.5	  ml	  microcentrifuge	  tube StarLab,	  UK I1415-­‐1000
7	  ml	  Bijou	  tube StarLab,	  UK E1412-­‐0710
Mouse	  restrainer Sigma,	  UK
Z756903
our	  restrainer	  was	  made	  in-­‐house,	  this	  is	  a	  
similar	  model
D-­‐Luciferin
